الفهرس 
Study of trail (tnfsf10) and tl1a (tnfsf15) gene variants in systemic lupus erythematous
AbstractOnly 14 pages are availabe for public view
 |  | from | 176 |  |  |
| | | from | 176 | | |
Abstract
Systemic lupus erythematosus (SLE) has two special features for apoptosis: irregular apoptosis and decline in the clearing of apoptotic bodies. Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) is a death ligand that causes apoptosis. Tumor necrosis factor superfamily 15 (TNFSF15), a special cytokine, could serve as a modulator of vascular homeostasis and inflammation and exert important functions on cell proliferation, activation, and differentiation of immune cells.
Objective: assessment the association between TRAIL (TNFSF10) 1525G/A and TL1A (TNFSF15) rs4979462 gene variants and SLE susceptibility and clinical outcomes.
Methods: A total of 123 patients diagnosed with SLE and 110 age and sex matched healthy control subjects were tested for TRAIL 1525G/A and TNFSF15 rs4979462 genotyping by PCR-RFLP, followed by confirmation of random samples from each genotype by direct sequencing technique and TNFSF15 concentration was measured in their serum using ELISA.
Results: Regarding TRAIL 1525G/A variant, there was a significant increase in the frequencies of combined genotypes (GA+AA) and A allele among cases when compared to the control group (P=0.049, OR= 1.727, 95% CI= 1.0 – 2.980; P = 0.021, OR= 1.73, 95% CI= 1.08 – 2.76, respectively). Regarding TNFSF15 rs4979462 gene variant, there was a significant increase in the frequencies of combined genotypes (CT+TT) and T allele among female cases when compared to the healthy female subjects (P = 0.025, OR= 2.644, 95% CI= 1.107 – 6.315; P = 0.014, OR= 2.75, 95% CI=1.20 – 6.32, respectively). The median serum TNFSF15 concentration was significantly higher in SLE patients [11.35 (10.0 – 14.55) ng/ml] when compared to the healthy control group [10.50 (9.62 – 12.17) ng/ml] (P=0.023).
Conclusions: TRAIL 1525G/A and TNFSF15 rs4979462 gene variants confer susceptibility to SLE risk, which is significantly associated with the clinical phenotypes of SLE and correlated with disease activity. TNFSF15 serum level could be a sensitive marker of SLE disease activity